Diabetes and Endocrinology: Recent Episodes
ReachMD
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nadia Merchant, MD
Guest: Melody Shi, MD
Guest: Despoina Galetaki, MD
Steroids are one of the main treatments for patients with Duchenne muscular dystrophy (DMD), but prolonged steroid use can come with many endocrine side effects, like weight gain, insulin resistance, and adrenal insufficiency. To learn more about these endocrine complications and surveillance, a recent survey was conducted, and here to share the results with Dr. Charles Turck are study authors Drs. Nadia Merchant, Melody Shi, and Despoina Galetaki.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Ian de Boer, MD
Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it’s essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.
Guest: Elena Toschi, MD
Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.
Host: John Buse, MD, PhD
Guest: Kim Boggess, MD
The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill.
Guest: R. Paul Wadwa, M.D.
Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.
Host: Carol Wysham, MD
Guest: A. Michael Lincoff, MD
Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Host: John Buse, MD, PhD
Guest: Louis J. Aronne, MD, FTOS
In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.
Host: Scott Kahan, MD, MPH
Guest: Ken Fujioka, MD
Guest: Carol Wysham, MD
Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management.
Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Maria Luiza Caramori, MD, PhD, MSc
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
Guest: Pam R. Taub, MD, FACC, FASPC
Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: John Buse, MD, PhD
Guest: Karen D. Corbin, PhD, RD
One of the biggest missing links in current literature about obesity and the gut microbiome was causality. In an effort to address that gap, a recent clinical trial was conducted, and now, the results are in. So what were the key findings, and how can we translate those findings into clinical practice? Find out how one’s diet can affect the gut microbiome with Dr. John Buse and Dr. Karen Corbin, an Investigator at the AdventHealth Translational Research Institute in Orlando, Florida.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Suijit Janardhan, MD, PhD
Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they’re particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush University Medical Center in Chicago.
Host: John Buse, MD, PhD
Guest: Anna Kahkoska, MD, PhD
Continuous glucose monitoring (CGM) can help improve glycemic management in patients with type 1 diabetes (T1D), but integrating this technology can be a complex learning process for older adults. So what do we need to consider when it comes to CGM use in older adults? Find out with Dr. John Buse and Dr. Anna Kahkoska, Assistant Professor in the Department of Nutrition and an Adjunct Assistant Professor in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill. Dr. Kahkoska is also the author of a recent paper, titled “Nothing is linear: Characterizing the determinants and dynamics of CGM use in older adults with type 1 diabetes.”
Host: Charles P. Vega, MD
Guest: Pradeep S. Prasad, MD, MBA
Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.
Host: John Buse, MD, PhD
Guest: Anastassios Pittas, MD, MS
Vitamin D has numerous benefits, and according to a recent study, it can even help reduce the risk of type 2 diabetes in patients with prediabtes. Learn more about the key findings from this research with Dr. John Buse and Dr. Anastassios Pittas, Professor of Medicine and Chief of Endocrinology at Tufts Medical Center.
Host: John Buse, MD, PhD
Guest: Viral Shah, MD
Severe hypoglycemia can lead to dangerous challenges, one of them being an increase in vehicular accidents. Dive into the results from a study that investigated the correlation between the prevalence of hypoglycemia while driving in adults with type 1 diabetes (T1D) and how many of those cases might have led to vehicular accidents with Dr. John Buse and Dr. Viral Shah, Associate Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes.
Host: Charles P. Vega, MD
Guest: Ruth Shoge, OD, MPH, FAAO
Racial and ethnic minorities are disproportionately affected by diabetic eye disease, which is one of the leading causes of vision loss in the United States. Hear how Dr. Ruth Shoge and Dr. Charles Vega are approaching patient care and find out what tools are available to you. Join us in overcoming barriers to vision care so that all patients can receive the treatment they need.
Host: Charles P. Vega, MD
Guest: Sharon D. Solomon, MD
New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who are less likely to access routine healthcare. Tune in to hear Dr. Sharon Solomon and Dr. Charles Vega discuss how the latest clinical data measure up by prolonging treatment intervals and how retina specialists are now better equipped to care for their most vulnerable patients with DME.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Scott D. Isaacs, MD FACP, FACE
Since type 2 diabetes is the number one risk factor for the progression to advanced liver fibrosis, monitoring diabetic patients is absolutely critical, especially considering the fact that the symptoms of disease progression can be nonexistent or very vague. Here with Dr. Mary Katherine Cheeley to break down the latest guidelines and strategies for monitoring liver health in patients with diabetes is endocrinologist Dr. Scott D. Isaacs.
Host: John Buse, MD, PhD
Guest: Jennifer B. Green, MD
The COORDINATE Study evaluated patients with cardiovascular disease and type 2 diabetes who encounter barriers in receiving newer diabetes medications. To better understand these gaps in care, Dr. John Buse speaks with one of the researchers, Dr. Jennifer Green from Duke University in Durham, North Carolina.
Host: John Buse, MD, PhD
Guest: Ania Jastreboff, MD, PhD
Counseling patients with obesity who are on GLP-1 receptor agonists can be challenging. How can we leverage the biology of GLP-1 receptor antagonists to improve weight loss while avoiding side effects? Dr. John Buse speaks with a leading expert in the field, Dr. Ania Jastreboff, about the role of GLP-1 receptor agonists in weight loss.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamy Ard, MD
Guest: Michelle I. Cardel, PhD, MS, RD
Addressing obesity may be a key component of diabetes management, so integrating strategies to manage obesity may improve diabetes care. To better understand this, Dr. Jamy Ard and Dr. Michelle Cardel dive into the impact of evidence-based lifestyle interventions for people living with diabetes.
WW Logo and Weight Watchers are the trademarks of
WW International, Inc. and are used with permission.
Host: John Buse, MD, PhD
Guest: Abbie E. Smith-Ryan, PhD, CSCS*D, FNSCA
There are immeasurable benefits to exercise, but the hard part for patients may be getting started. How can we help our patients make exercise a part of their lives? Dr. John Buse speaks with Dr. Abbie Smith-Ryan, a Professor of Exercise Physiology at the University of North Carolina – Chapel Hill, about the key benefits of exercise and how to encourage them for various patient populations.
Host: Mark A. Atkinson, PhD
Guest: Linda DiMeglio, MD, MPH
Autoantibody Screening to Identify Risk for Type 1 DiabetesT1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.
Host: John Buse, MD, PhD
Guest: Sue Pedersen, MD, FRCPC
New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.
Host: John Buse, MD, PhD
Guest: Silva Arslanian, MD
New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians’ approach to care. What do we need to know? Dr. John Buse speaks with one of the study’s investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment landscape.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
Guest: Scott D. Isaacs, MD FACP, FACE
Recently, the American Association of Clinical Endocrinology and the American Association for the Study of Liver Diseases released guideline updates on nonalcoholic steatohepatitis (NASH). How will these updates impact clinical practice? Drs. Zobair M.Younossi and Scott D. Isaacs join Dr. Charles Turck to share their insights on these updated guidelines.
Host: John Buse, MD, PhD
Guest: Jennifer B. Green, MD
What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study’s investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Donovan, PhD, MD
Diabetic kidney disease (DKD) can be burdensome for patients—especially if it progresses. How can we find out if our patients are at risk of progression? To answer that question, Dr. Charles Turck is joined by Dr. Michael Donovan to discuss a prognostic tool for type 2 diabetes patients with early-stage (stage 1-3b) chronic kidney disease.
Host: John Buse, MD, PhD
Guest: Deborah Wexler, MD
The GRADE study demonstrated the efficacy of different treatment options for patients with type 2 diabetes. To learn more about these treatment options, Dr. John Buse joins one of the study’s investigators, Dr. Deborah Wexler from Harvard Medical School and the Massachusetts General Hospital Diabetes Center, to dive into this study.
Host: Jennifer Caudle, DO
Guest: Joseph Aloi, MD
The rate of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) continues to rise. What can we do to slow this progression of CKD? Dr. Joseph Aloi from the Wake Forest School of Medicine explores this growing epidemic and discusses how a new tool may aid in early risk assessment of early stage 1-3b CKD.
Host: John Buse, MD, PhD
Guest: Martin de Bock, PhD FRACP
Recent research has explored the efficacy of open source automated insulin delivery devices for patient with type 1 diabetes. What did these results tell us? Dr. John Buse speaks with Dr. Martin de Bock, a pediatric endocrinologist at the University of Otago in Christchurch, New Zealand, to dive deeper into this research.
Host: John Buse, MD, PhD
Guest: Matthew Crowley, MD
Can telehealth change the way we manage persistently controlled type 2 diabetes (PPDM)? Dr. John Buse speaks with Dr. Matt Crowley, an Associate Professor of Medicine in the Department of Medicine in the Division of Endocrinology, Metabolism and Nutrition at Duke University, to explore some of the research on different methods of telehealth.
Host: John Buse, MD, PhD
Guest: Seth Berkowitz, MD, MPH
Food assistance programs like the Supplemental Nutrition Assistance Program (SNAP) can help relieve food insecurity. But can they also lower healthcare spending? To answer this question, Dr. John Buse sits down with Dr. Seth Berkowitz from the Division of General Medicine and Clinical Epidemiology at the University of North Carolina School of Medicine.
Host: John Buse, MD, PhD
Guest: Ashok Balasubramanyam, MD
Researchers from the GRADE study zeroed in on islet autoimmunity in beta cell dysfunction for patients with type 2 diabetes. What did various treatment options show us? Dr. John Buse speaks with Dr. Ashok Balasubramanyam, a Professor in the Department of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine.
Host: John Buse, MD, PhD
Guest: Jose C. Florez, MD, PhD
Precision medicine may be the future of diabetes treatment. But what’s needed to implement this approach into practice? Here to explore this concept with Dr. John Buse is Dr. Jose Florez, Chief of the Endocrine Division and Diabetes Unit at the Massachusetts General Hospital.
Host: John Buse, MD, PhD
Guest: Carolyn Bramante
Emerging research has shed light on the possibility of generic drugs being repurposed for the treatment of COVID-19. Dr. John Buse discusses metformin, ivermectin, and fluvoxamine with Dr. Carolyn Bramante, an Assistant Professor in the Division of Geriatrics, Palliative and Primary Care at the University of Minnesota Medical School.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Yehuda Handelsman, MD
The National Lipid Association (NLA) and the American College of Cardiology (ACC) recently provided recommendations to help us achieve optimal low-density lipoprotein (LDL) levels in statin-intolerant patients, but what other management strategies are available? Joining Dr. Charles Turck to answer this question and to give more key insights is Dr. Yehuda Handelsman, Medical Director and Principal Investigator at the Metabolic Institute of America.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Javier Morales, MD, FACP, FACE
Guest: Angela Yee-Moon Wang, MD, FACP, FACE
Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.
Host: John Buse, MD, PhD
Guest: Domenica M. Rubino, MD
The obesity epidemic affects millions of patients around the world, but a new treatment option may be a game-changer for the treatment landscape. Lead author of the STEP 8 clinical trial, Dr. Domenica Rubino, joins Dr. John Buse to share the insights from this drug trial and how these key clinical findings may impact the obesity treatment landscape.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: John Buse, MD, PhD
Guest: Anastasia-Stefania Alexopoulos, MBBS, MHS
Dr. John Buse joins Dr. Anastasia-Stefania Alexopoulos, an endocrinologist, researcher, and Assistant Professor of Medicine in the Department of Medicine at Duke University School of Medicine to share her research on the deintensification of hypoglycemia-inducing medications in diabetic adults.
Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.
Since 2020, pediatricians have seen a rapid rise in new-onset type 1 diabetes in children. Is this due to the COVID-19 pandemic or an indirect consequence of it? To answer this question, Dr. Jane Kim, a pediatric endocrinologist at Rady Children's Hospital in San Diego, shares what kind of correlation she's seeing.
Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.
Emerging research details a rapid rise in type 1 diabetes in children amid the COVID-19 pandemic. But what's causing this to happen? To dive into why, Dr. Carol Wysham is joined by Dr. Jane Kim from the Rady Children's Hospital in San Diego.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eugene E. Wright, Jr., MD
Guest: Marina Basina, MD
What are some ways we can detect chronic kidney disease in patients with type 2 diabetes early? Joining Dr. Charles Turck to share collaborative strategies for early detection are Dr. Marina Basina from Stanford University Medical Center and Dr. Eugene Wright from the Charlotte Area Health Education Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Alexis McKee, MD
What communication strategies can we use to create personalized treatment plans and improve adherence among our patients with type 2 diabetes? That’s the exact question Dr. Charles Turck discusses with Dr. Alexis McKee, an Assistant Professor of Medicine in the Division of Endocrinology, Metabolism, and Lipid Research at the Washington University School of Medicine in St. Louis.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Javier Morales, MD, FACP, FACE
There are several factors to consider when determining if insulin is the right treatment option for a patient with type 2 diabetes. And once a patient is prescribed insulin therapy, it’s just as important to consider the factors that might lead to nonadherence. That’s why Dr. Charles Turck speaks with Dr. Javier Morales about those factors and how we can improve our patients’ adherence to their insulin regimens.
Host: Carol Wysham, MD
Guest: Rodica Pop-Busui, MD, PhD
Type 2 diabetes can be reflected in a patient's oral health, but can we say the same for patients with type 1 diabetes? Here to dive into that question and to share her latest findings in oral health in patients with type 1 diabetes is Dr. Rodica Pop-Busui, a Larry D. Soderquist Professor of Diabetes and Vice-chair for Clinical Research in the Department of Internal Medicine and also the Director of Clinical Research, Mentoring and Development of M-Diabetes at the University of Michigan.
Guest: Claresa Levetan, MD
Diabetes impacts around 40 million Americans and 25% of them don't even know they have it. Luckily, Diabetes Alert Day was created to spread awareness of this widespread disease. To help us understand this campaign, Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares insights on the importance of Diabetes Alert Day.
Host: John E. Anderson, MD
Guest: Scott Pilla, MD, MHS
One of the most serious side effects of diabetes, hypoglycemia can lead to severe consequences, and keeping up with the latest in care can help us prevent this complication. To share the latest updates, Dr. John Anderson is joined by Lead Researcher Dr. Scott Pilla to share insights from his recent studies on hospital utilization and primary care communication for patients with diabetes.
Host: Ruth S. Weinstock, MD, PhD
Guest: Susan B. Bressler, MD
Guest: Mark Dunbar, OD, FAAO
With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?
Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.
Host: Eugene E. Wright, Jr., MD
Guest: Jolanta Małyszko, MD, PhD
Guest: María José Soler, MD, PhD
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
Host: Rahul N. Khurana, MD
Guest: Jennifer K. Sun, MD, MPH
The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?
Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.
Host: Carol Wysham, MD
Guest: Deepak Vashishth, PhD
Guest: Bowen Wang
Can we predict when a patient with COVID-19 requires hospitalization? To answer this question, Dr. Carol Wysham is joined by Dr. Deepak Vashishth and Mr. Bowen Wang from the Rensselaer Polytechnic Institute to share data from their study on the impact of glycemic levels and common medications on COVID-19 severity in patients with type 2 diabetes.
Host: John E. Anderson, MD
Guest: Elizabeth A. Beverly, PhD
Current treatment strategies for diabetic patients focus on behavioral and clinical targets alone, but can shared experiences and peer support improve care? To learn more about this, Dr. John Anderson talks to Dr. Elizabeth Beverly from the Ohio University Heritage College of Osteopathic Medicine to discuss her recent study on positive experiences for patients living with type 1 or type 2 diabetes.
Host: Jayanth Sridhar, MD
Guest: Avni P. Finn, MD, MBA
Are you aware of the latest data that adds to our understanding of the management of diabetic retinopathy (DR)? Listen in as Dr. Avni Finn and Dr. Jay Sridhar discuss what those data are and the impact they have on the early referral and timely treatment of patients with DR. Make sure you’re properly using all of the resources in your armamentarium to save your patients’ sight.
Guest: George L. Bakris, MD
From diagnostic criteria to risk stratification, what do we need to know about recognizing early-stage diabetic kidney disease? Dr. George Bakris from the University of Chicago Medicine discusses detection strategies for diabetic kidney disease.
Host: Diana Shechtman, OD, FAAO
Guest: Carolyn E. Majcher, OD, FAAO
When it comes to diabetic retinopathy, studies and new data are constantly being published. Are you up to date with the progress being made? Join Dr. Diana Shechtman and Dr. Carolyn Majcher for a discussion on the latest data around the treatment of nonproliferative diabetic retinopathy and how these advances affect the management of your patients.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Eliza B. Geer, MD
The primary goals in the medical management of Cushing’s disease are to normalize cortisol levels and reduce or eliminate the associated comorbidities, physical features, and symptoms for our patients. With recently approved therapies and more in development, it really is an exciting time in this treatment space! Tune in to hear Dr. Eliza Geer discuss novel medical options and how we should remember the importance of looking at patient outcomes to make sure we’re addressing Cushing’s disease holistically.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Peter Libby, MD
Guest: Lawrence A. Leiter, MD
Guest: Prof. Kausik Ray, MBChB, MD, MPhil
This CME Roundtable highlights key takeaways and late-breaking data shared at a symposium held at the AHA annual meeting. Hear updated management strategies, new data, and guidelines to help you manage patients with established ASCVD who are at an increased risk of myocardial infarction, stroke, and death.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Robert J. Chilton, DO
Guest: John R. Nelson, MD, FACC, FNLA, FASNC
Join Drs. Chilton and Nelson as they discuss recent omega-3 fatty acid (OM-3) outcomes trial results and how to apply those results along with evidence-based guidelines to reduce ASCVD risk. Tune in to hear about the use of OM-3s including dietary supplement OM-3s that are readily available in pharmacies and online, so you can keep your patients informed!
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Emily Louise Johnson, MD
According to recent estimates, between 150,000 and 450,000 transgender patients have epilepsy. And as that number is only expected to grow, Assistant Professor of Neurology at Johns Hopkins School of Medicine Dr. Emily Johnson shares key considerations for treating transgender patients with epilepsy.
Host: John E. Anderson, MD
Guest: Simon Heller, MD
Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, and honorary consultant physician with the NHS Foundation Trust in the United Kingdom, reflects on the steps we can take to prevent severe hypoglycemia and reduce cardiovascular risk in diabetic patients.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
John Anderson joins fellow Diabetes Discourse hosts John Buse and Carol Wysham to explore exciting clinical trial results presented at this year's Scientific Session of the American Diabetes Association.
Host: John E. Anderson, MD
Guest: Michael Greenberg, MD
Dr. John Anderson joins Dr. Michael Greenberg, host of DermConsult, to discuss skin diseases that dermatologists should be aware of in patients with diabetes.
Guest: Carol Wysham, MD
ReachMD host Dr. Carol Wysham discusses what we currently know about hypoglycemia and cardiovascular disease, how to identify patients at risk for severe hypoglycemia, and the strategies and approaches to mitigate risk of hypoglycemia.
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: Leslie Cho, MD
More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!
Guest: David M. Simpson, MD
Guest: Jon T. Gertken, MD
Guest: Stephanie Simon, NP
Find the full Prescribing Information here.
There are multiple ways to incorporate the use of Qutenza, a topical treatment for painful diabetic peripheral neuropathy of the feet, into practice. Tune in to hear Dr. David M. Simpson, Dr. Jon T. Gertken, and Ms. Stephanie Simon share their best practices for administering Qutenza as well as the management of painful diabetic peripheral neuropathy of the feet.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
© 2021 Averitas Pharma, Inc. All rights reserved.
M-QZA-US-01-21-0065 June 2021
Guest: Kevan C. Herold, MD
Guest: Andrea Steck, MD
Guest: Anette Gabriele Ziegler, MD
Experts in the immunopathology of type 1 diabetes review data showing that clinical presentation is preceded by an asymptomatic phase, characterized by the presence of one or more islet autoantibodies. Screening children for islet autoantibodies during the two preclinical stages can identify those with multiple autoantibodies and high-risk antibody phenotypes who may be candidates for preventive interventions before developing dysglycemia or the clinical onset of type 1 diabetes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Alexis McKee, MD
Since patients with type 2 diabetes on multiple daily injections of insulin are at high risk of hypoglycemia, Dr. Charles Turck discusses essential counseling strategies for these high-risk patients with Dr. Alexis Mckee, an endocrinologist and Assistant Professor of Medicine at Washington School of Medicine in St. Louis, Missouri. Together, they’ll review how we can help patients avoid, manage, and treat hypoglycemia emergencies.
Guest: Brett Nowlan, MD
Metabolic dysfunction is the central driver for conditions with some of the highest mortality rates. Identifying this dysfunction early on is essential to preventing disease progression. Dr. Brett Nowlan, a cardiologist at Cottage Grove Cardiology in West Hartford, Connecticut, explains why.
Host: Michael Miller, MD, FACC, FAHA, FNLA
Guest: Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% reduction in major cardiovascular events. In 2020, the STRENGTH trial that used a carboxylic acid formulation of combined EPA and docosahexaenoic acid (DHA), was surprisingly neutral and the study was halted for futility. A recent post hoc analysis of the STRENGTH study failed to show a difference in the primary endpoint in the highest tertile group receiving the EPA/DHA carboxylic acid treatment. Why did these two major omega-3 clinical trials studying patients with elevated triglyceride levels have disparate results? What does this mean for our patients? Join two experts, Drs. Michael Miller and Brian Olshansky, as they assess the different trials and offer their perspective on the clinical and scientific implications of the results.
Guest: Kevan C. Herold, MD
Guest: Stephen Gitelman, MD
Experts in the immunopathology of type 1 diabetes consider the potential role of monoclonal antibodies, disease modifying agents, and other agents to prevent or delay the onset of clinical disease. Particular emphasis will be placed on the CD3 cell surface marker and anti-CD3 monoclonal antibodies, which has been shown to slow progression to clinical type 1 diabetes in high risk persons.
Host: Christina Y. Weng, MD, MBA
Guest: Arshad M. Khanani, MD, MA
Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.
Host: Vivian Fonseca, MD, FRCP
Guest: Rishi P. Singh, MD
Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of therapy or the provision of suboptimal therapy often negatively impact the quality of life of these patients. Join us for this expert interview with Dr. Susan Samson and Dr. Kevin Yuen who offer insights to help you overcome the complex medical challenges often faced when managing patients with acromegaly, including strategies to apply the latest guidelines and the 2020 consensus statement into clinical practice.
Host: John E. Anderson, MD
Guest: Raghu Mirmira, MD,PhD
When treating type 1 diabetes, should we be focusing on disease prevention rather than reversal? Dr. John Anderson takes a look at prevention tactics for type 1 diabetes progression with Dr. Raghu Mirmira, a Professor of Medicine and the Director of the Translational Research Center at the University of Chicago.
Guest: Kevan C. Herold, MD
Guest: Chantal Mathieu, MD, PhD
Experts in the immunopathology of type 1 diabetes discuss the epidemiology, non-genetic and genetic risk factors, and progression from preclinical to clinical stages of this disease. The discussion will emphasize the breakdown of immune tolerance that precedes type 1 diabetes and the subsequent pathogenetic role of islet autoantibodies responsible for its clinical manifestations.
Host: Carol Wysham, MD
Guest: Irl Hirsch, MD, MACP
Why was there so much discordance between some patients’ GMI and their measured A1C? That’s the exact question Dr. Irl Hirsch from the University of Washington School of Medicine asked and explored in a paper he recently co-authored. And now Dr. Hirsch is here to share his findings.
Host: John Buse, MD, PhD
Guest: Anne Louise Peters, MD
SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.
Host: Hector O. Chapa, MD, FACOG
Guest: Andrew Little, DO
When vascular access is compromised, intraosseous access, or IO access, can help prevent fatal consequences. What do we need to know about implementing and managing this type of device? Dr. Hector Chapa is joined by Dr. Andy Little, the Associate Program Director for AdventHealth Orlando Emergency Medicine Residency, to share some insight on IO vascular access.
Host: John Buse, MD, PhD
How early should we start screening for diabetes, and what tools are available to us? In recognition of Diabetes Alert Day, Dr. John Buse reviews the current screening tests and recommendations for those who are at risk of diabetes.
Host: John E. Anderson, MD
Guest: Matthias Hebrok, PhD
Emerging research may offer clinicians an alternative approach to treating type 1 diabetes. Dr. John Anderson meets with Dr. Matthias Hebrok, a professor in diabetes research and director of the Diabetes Center at the University of California, San Francisco, to discuss his groundbreaking research on insulin-producing stem cells.
Host: John E. Anderson, MD
Guest: Matthias Hebrok, PhD
What are the effects of type 1 diabetes on the body? Dr. Matthias Hebrok, a professor in diabetes research and director of the Diabetes Center at the University of California, San Francisco shares some insight on type 1 diabetes and its chronic impact on patients.
Host: Carol Wysham, MD
Guest: Alexis McKee, MD
Patient care has evolved amid the COVID-19 pandemic, causing unexpected challenges in managing diseases such as diabetes. Dr. Carol Wysham joins Dr. Alexis McKee, a practicing endocrinologist and an assistant professor of medicine at Washington School of Medicine in St. Louis, Missouri, to discuss how patients have been overcoming challenges in managing diabetes during the pandemic.
Host: John Buse, MD, PhD
Guest: David Wheeler, MB, CHB, MD, FRCP
Recent research has revealed that a type 2 diabetes treatment may help manage chronic kidney disease. Dr. John Buse discusses the use of dapagliflozin in patients with chronic kidney disease with Dr. David Wheeler, a professor of kidney medicine at the University College London in the United Kingdom, and an honorary consultant nephrologist at the Royal Free London NHS Foundation Trust.
Host: Carol Wysham, MD
Guest: Janet B. McGill, MD, MA, FACE, FACP
Many patients with diabetes don’t fit into our stereotypes of type 1 or type 2 diabetes and identifying them is key to understanding how to treat them. Dr. Carol Wysham discusses atypical diabetes with Dr. Janet McGill, a professor of medicine at the Washington School of Medicine in St. Louis, Missouri.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua Stolker, MD
Patients with type 2 diabetes face a higher risk of cardiovascular morbidity and mortality than adults without diabetes. How does this understanding specifically affect the way cardiologists manage their patients with type 2 diabetes? Joining Dr. Charles Turck to explore recently updated recommendations and their impacts on cardiology practice is interventional cardiologist Dr. Joshua Stolker.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00435 February 2021
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
With an explosion in new medications to treat diabetes, Heart Matters hosts Dr. Matthew Sorrentino and Dr. Alan Brown sit down to discuss the cardiovascular risk benefits of these new diabetes treatments and how cardiologists can improve patient care.
Guest: Joshua Stolker, MD
The 2020 American College of Cardiology Expert Consensus Decision Pathway provides a change in mindset for the cardiology field when it comes to treating patients with type 2 diabetes with established cardiovascular disease. Here to walk us through these updated recommendations is Dr. Joshua Stolker, an interventional cardiologist at Mercy Clinic Heart and Vascular in Saint Louis, Missouri.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00430 January 2021
Host: John E. Anderson, MD
Guest: Jason Sloane, MD
There’s no denying that the COVID-19 pandemic has impacted every aspect of healthcare. So in an effort to recognize those who’ve gone above and beyond the call of duty, ReachMD’s Heroes in Healthcare initiative honors those healthcare professionals who were nominated by their peers for their outstanding contributions to the field of medicine. And one such nominee, Dr. Jason Sloane, joins Dr. John Anderson to discuss this nomination, strategies for optimal care, and his response to the COVID-19 pandemic.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
Physical activity is a valuable tool in treating patients with type 2 diabetes. But there are several factors clinicians must consider before prescribing exercise, including patient preference and limitations. Dr. John Anderson sits down with Dr. John Jackicic, Professor in the Department of Health and Physical Activity at the University of Pittsburgh, to discuss considerations when prescribing exercise to patients with type 2 diabetes.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
Dietary decisions play a critical supporting role in the treatment of patients with type 2 diabetes. What kind of impact do these nutritional interventions have? Dr. Kathleen Stanley, a registered dietitian and certified diabetes educator with the Baptist Health Center joins Dr. John Anderson to discuss the impact of dietary recommendations on patients with type 2 diabetes.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
Adhering to treatment can be challenging for many patients with diabetes. Especially for patients on bolus insulin, how can we encourage them to stick to treatment? Tune in to hear Diabetes Discourse hosts Drs. John Buse, Carol Wysham, and John Anderson discuss a patient case and strategies to overcome it.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
The wintertime presents new challenges for patients with chronic diseases, specifically diabetes. But with the spread of COVID-19, how can we help keep our patients safe all winter long? Tune in to hear our Diabetes Discourse hosts Drs. Carol Wysham, John Buse, and John Anderson discuss strategies to effectively manage patients with diabetes during these winter months.
Published December X, 2020
Guest: Pablo F. Mora, MD
The glycemic control algorithm that’s part of the American College of Endocrinology Consensus Statement for 2020 is separated into several parts, and here to break them down for us is Dr. Pablo Mora, Clinical Professor with the Division of Endocrinology at the University of Texas Western Medical Center of Dallas.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00336 October 2020
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
The outbreak of the COVID-19 pandemic has pushed healthcare professionals to adjust the way they treat patients with chronic conditions like diabetes. Tune in to hear Drs. John Anderson, John Buse, Carol Wysham share their experience caring for patients with diabetes amid the pandemic.
Host: Jennifer Caudle, DO
Guest: Lisa A. Coco, CRNP
Guest: Deborah Hinnen, APN, BC-ADM, CDCES, FAAN
Guest: Davida F. Kruger, CNP
When a patient with diabetes has cardiovascular disease, they’re at greater risk for morbidity and mortality. That’s why the American Diabetes Association’s 2020 Standards of Medical Care in Diabetes aim to address this and other health risks, and here to walk us through this new treatment algorithm are nurse practitioners Lisa Coco, Debbie Hinnen, and Davida Kruger.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00343 October 2020
Host: Linda Bernstein, Pharm.D.
On this episode of The Drug Report, pharmacist Dr. Linda Bernstein focuses on a recent CVS Health announcement of their new plan that allows employers and health plan sponsors to work within a formulary and plan design to offer all types of diabetes medications—including insulin—at zero-dollar out of pocket for their members without raising costs for the plan sponsor or increasing premiums or deductibles for all plan members.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Paul Orchard, MD
Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That’s why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it’s often underdiagnosed and confused with other conditions, and how we can treat it once we’ve reached an accurate diagnosis.
Host: Barnett Mennen, MD
Guest: Sarah Hallberg, MD
Carbohydrates are our main source of energy and provide important nutrients for good health. However, they are also the main culprit behind elevated blood sugar and are problematic for diabetic patients trying to control their blood sugar levels.
Host Dr. Barry Mennen sits down with Dr. Sarah Hallberg to talk about carbohydrate restriction as a key to successful weight loss programs. She prescribes that adherence to a low-carb, high-fat diet is vital to patients for controlling their diabetes, with the possibility of being able to come off medications over time.
Dr. Sarah Hallberg is the Medical Director at Virta Health and Founder of the Indiana University-Arnett Health Medical Weight Loss Program in Lafayette, Indiana.
Host: Brian P. McDonough, MD, FAAFP
According to the United States Department of Agriculture, the average American consumes between 150 to 170 pounds of refined sugars every year. Excessive sugar consumption is linked to a long list of health problems, from obesity and cardiovascular disease to joint inflammation and ADHD, but most of us can’t seem to be able to stop eating sugar no matter how hard we try.
Joining Dr. Brian McDonough to address the growing threat of sugar addiction is health educator and wellness expert Dr. David Magnano.
Host: Matt Birnholz, MD
Guest: Denise Devine
What if there was a way to monitor vital signs in real time? Denise Devine, Co-Founder of RTM Vital Signs, LLC, is working on just that. She is joined by Dr. Matt Birnholz at the Villanova Health Summit to discuss this innovative technology in development, which opens up the possibility of collecting continuous health data from patients to enhance point-of-care treatments.
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.
Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.
Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov.
Released 5/16/2017
Host: Jennifer Caudle, DO
Guest: Leah Sarris, RD, LDN
It's important for physicians to know how to talk to their patients about healthy eating habits and smart dietary choices, which can be a difficult conversation to have. Tulane Medical School is trying to overcome this obstacle by teaching their medical students how to cook, hoping that it translates into better communication with patients in the future.
Host Dr. Jennifer Caudle explores this innovative program with Chef Leah Sarris, a registered dietitian and Director of Operations and Executive Chef at the Goldring Center for Culinary Medicine at Tulane University School of Medicine. They talk about ways in which teaching culinary medicine to medical students is leading to healthy eating habits and improved outcomes for the larger community.
Host: Brian P. McDonough, MD, FAAFP
Diabulimia, defined as the manipulation of insulin treatments by Type 1 diabetic patients in order to lose weight, is a rising problem among teens and young adults in the U.S, particularly young women. Joining Dr. Brian McDonough to discuss this dual diagnosis phenomenon of diabetes and eating disorders, ways in which they exacerbate other disease processes, the long term consequences, and management priorities for phycisians is author and registered dietitian Susan Weiner. Susan is a recipient of the AADE Diabetes Educator of the Year award and has devoted much of her writing and clinical expertise to addressing diabulimia in at-risk patients.
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
Many menopausal and perimenopausal women are faced with the decision of whether synthetic or bioidentical hormone therapy is the best option for them. There are many pros and cons for each, but questions surface from patients and clinicians alike on comparative safety and efficacy profiles.
Host Dr. Renee Allen welcomes Dr. Jocelyn Slaughter-Moore, a board-certified practicing OB/GYN at Heras Healthcare for Women. They talk about the differences between bioidentical and synthetic hormones, and whether bioidentical hormone therapy is a safe option for women.
Host: Shira Johnson, MD
Guest: Charles N. Walker, MD
Dr. Shira Johnson speaks with Dr. Charles Walker, Assistant Professor of Surgery in the Department of Urology at Yale University School of Medicine. The two focus on erectile dysfunction as a common complication for patients dealing with diabetes and heart disease, and ways that clinicians can help patients manage this problem through lifestyle modifications. Dr. Walker also introduces emerging pathophysiological understandings of ED as a potential predictor of diabetes.
[Read the Article]
Despite targeted efforts to reduce obesity through diet and exercise, these rates continue to rise. A new study from Ontario, Canada found that obesity and diabetes rates were lower in more walkable neighborhoods compared to less walkable neighborhoods, where they saw an increase in these rates.
Researchers from St. Michael's Hospital in Toronto studied almost 9,000 neighborhoods in Southern Ontario looking at walkability scores, along with government health data and survey results during a twelve-year period. They examined whether neighborhoods that were more walkable experienced a slower increase in obesity and diabetes compared to less walkable neighborhoods.
[Watch more videos of The JAMA Report]
Host: Brian P. McDonough, MD, FAAFP
Guest: Tina Kaur Thethi, MD, MPH, FACE
Dr. Brian McDonough welcomes Dr. Tina Thethi, Assistant Professor of Medicine in the section of Endocrinology and Metabolism at Tulane University Health Sciences Center. The two discuss pharmacologic and non-pharmacologic treatment options for obesity, with an eye on longer term management strategies to curtail the development of diabetes after lifestyle modifications fall short of target goals.
Host: Jennifer Caudle, DO
Host Jennifer Caudel, DO welcomes Jay Shubrook, DO, Director of Clinical Research and Diabetes Services at Touro University-California College of Osteopathic Medicine. Recorded on site at the American Osteopathic Association's annual medical education conference, Dr. Shubrook discusses a pilot study in which newly diagnosed type 2 diabetes patients were treated with early insulin rather than lifestyle changes and oral therapies alone. The results suggested not only good safety profiles, but also better long-term outcomes for patients.
[Read the Article]
Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the procedure has many side effects including permanent loss of peripheral vision and swelling of the retina.
A group of researchers from across the US tested an alternative treatment using an injectable medication called ranibizumab, to see if it would be as effective as the laser therapy. They studied more than 300 patients with PDR, assigning them to either receive standard laser therapy or an injection into the eye. In total, they treated close to 400 eyes.
Outcomes, especially loss of vision, were compared at two years. Over the two year period, researchers found that patients receiving the injections of medication had fewer side effects and did somewhat better in terms of vision loss than those who received laser therapy.
[Watch more videos of The JAMA Report]
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Dr. Marcy Lake, faculty member of the Kaiser Permanente Family Medicine Residency Program in Portland Oregon and author of a recent article in American Family Physician devoted to disorders of the pituitary gland. Their discussion tours diagnostic considerations toward the workup of pituitary diseases, and emerging treatment paradigms for clinicians at general, endocrinology, and surgical levels of care.
[Read the Article]
The popularity of testosterone supplementation among older men has increased substantially over the past decade. However, the risks and benefits of long-term administration are still unclear. A new study examined whether using testosterone supplements affected the development of atherosclerosis (hardening of arteries), which is linked to heart attack and stroke.
Researchers from Brigham and Women's Hospital in Boston studied more than 300 men who were sixty years of age and older, in relatively good health, and had low or low-normal testosterone levels. Half the men applied a testosterone gel daily to the skin for three years, while the other half were given a placebo gel. During the course of the trial, hardening of the arteries was measured in the carotid and coronary arteries, which supply the brain and heart.
Results were that during the three year study, there was no significant effects in terms of hardening of the carotid or coronary arteries. Testosterone supplementation also did not improve overall sexual function or health-related quality of life.
[Watch more videos of The JAMA Report]
JAMA Report videos provided pursuant to license. ©2015 American Medical Association, publisher of JAMA® and The JAMA Network® …
Host: John J. Russell, MD
Guest: Candis Morello, PharmD, CDE
Candis M Morello, Professor of Clinical Pharmacy at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, joins Dr. John Russell to talk about team-based care integrations of certified diabetes educators to help empower diabetes patients and improve long-term outcomes.
Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.
Brought to you by
Host: Brian P. McDonough, MD, FAAFP
How can pharmacy practice inform the primary care and family medicine communities about approaching challenging diabetes cases? Christa George, Pharm.D, Associate Professor in the departments of Clinical Pharmacy and Family Medicine at the University of Tennessee Health Science Center, joins Dr. Brian McDonough to discuss Type 2 Diabetes from the unique vantage point of the pharmacist.
Host: John J. Russell, MD
Guest: Candis Morello, PharmD, CDE
Host Dr. John Russell welcomes Candis M. Morello, PharmD., CDE, FCSHP, Professor of Clinical Pharmacy and Associate Dean for Student Affairs at the Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Morello explains the importance of patient education, communication, and motivation needed to instill a positive and healthy approach to diabetes care.
Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.
Brought to you by
Host: John J. Russell, MD
Guest: Neil Skolnik, MD
For clinicians managing patients with T2DM, the clinical landscape for standards of care, diagnostic methods and techniques, and treatment options has become increasingly complex. Yet despite this challenge in keeping up to date with the latest recommendations, updated practice guidelines have also made it a point to emphasize "big picture" elements in diabetes care, reinforcing mainstays of treatment that can potentially get overlooked.
On this episode, Dr. John Russell welcomes diabetes expert Dr Neil Skolnik, Associate Director of Family Medicine at Abington Jefferson Health, to explore the "Back to Basics" model in diabetes management, with emphasis on individualized therapeutic approaches and lifestyle modification strategies for improving long-term patient outcomes.
Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.
Brought to you by
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Dr. Tina Thethi, Assistant Professor of Medicine in the section of Endocrinology and Metabolism at Tulane University Health Sciences Center. Dr. Thethi provides the inside scoop on diabetes topics of particular interest to endocrinologists in practice today, from pre-diabetes management to continuous glucose monitoring to novel drug research and development.
Host: Shira Johnson, MD
Guest: Meryl S. LeBoff, MD
Osteoporosis is a major public health threat for an estimated 54 million Americans 50 years of age and older. In the U.S. today, 10.2 million individuals are estimated to already have the disease and 43.4 million more are estimated to have low bone mass, placing them at increased risk for osteoporosis and fractures. Because bone density tends to decline with age, the problem of osteoporosis has reached epidemic proportions with the rapidly aging population. It is estimated that by 2020 over 61 million Americans will have osteoporosis or low bone mass. Join host Dr. Shira Johnson welcomes Dr. Meryl LeBoff, Endocrinologist; Chief of the Calcium and Bone Section at Brigham Women's Hospital in Boston, Massachusetts; and, trustee of the National Osteoporosis Foundation.
About NOF & Fracture Liaison Service (FLS)
NOF has adopted the 20/20 Vision of the National Bone Health Alliance (NBHA), of which NOF is a founding member. The goal is to reduce bone breaks by 20% by the year 2020.
Approximately 2 million fractures are caused by osteoporosis each year. Compliance around osteoporosis and post-fracture quality measures is not consistent despite the existence of several NCQA and CMS healthcare provider quality measures. The solution to resolving the 75 …
Host: Maurice Pickard, MD
Obesity and sedentary activities have contributed to an epidemic of diabetes mellitus in the US. Is there an answer that is not simply a "fad" diet? Joining host Dr. Maurice Pickard to address this important question is Dr. Osama Hamdy, Medical Director of the Weight Management Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School. Dr. Hamdy is co-author of Diabetes Breakthrough: Better Health in Just 12 Weeks.
The Gender, Sexuality and HIV Prevention Center at Ann & Robert H Lurie Children's Hospital of Chicago is the first of its kind facilty for adolescent patients. Host Dr. Jennifer Caudle welcoms the center's director, Dr. Robert Garofalo. Dr. Garofalo will share the center's mission of supporting multidisciplinary academic subjects including sexual health, gender, sexuality, HIV prevention and health disparities which affect adolescent and young adult populations at risk of acquiring HIV. The Center partners with similar organizations throughout the country in creating an environment where clinicians, academics and scientists can collaborate to design projects with public health significance.
Robert Garofalo, MD, MPH, is Professor of Pediatrics and Preventive Medicine at Northwestern University Feinberg School of Medicine. He is also an Attending Physician at Lurie Children's, where he directs the Adolescent/Young Adult HIV Program. Dr. Garofalo is a national authority on LGBT health issues, adolescent sexuality, and HIV clinical care and prevention.
Host: Brian P. McDonough, MD, FAAFP
Dr. McDonough discusses new Breathalyzer technology introduced at the 2013 American Association of Pharmaceutical Scientists Annual Meeting that may one day eliminate the need for finger sticks for diabetics.
Host: Prathima Setty, MD
As health care providers, despite our knowledge and empathy of patient experiences, we may become distanced from the day-to-day life of coping with chronic diseases such as diabetes. Host Dr. Prathima Setty welcomes Dr. Svetlana Katsnelson, an Endocrinology Fellow from Stony Brook University Medical Center in Stony Brook, New York to discuss her experience in living the life of patient with diabetes for one week. Dr. Katsnelson provides a "behind-the-scenes" account that led her to better understand how patients cope with strict timelines for eating and medicating, as well as complying with complicated devices that monitor blood glucose levels. Through this brief journey, Dr. Katsnelson came into greater awareness for how difficult it is to live with diabetes.
Download and listen today!
Host: Linda Bernstein, Pharm.D.
In this edition of The Pharmacy Report®, host Dr. Linda Bernstein spotlights type 1 diabetes and the new paradigms of research in disease detection, prevention and treatment. In the Movers and Shakers segment, Dr. Stephen E. Gitelman, M.D., Professor of Clinical Pediatrics and Chair of Pediatric Diabetes and Clinical Research at the University of California, San Francisco shares his fascinating path of discovery and research into this complex disease and how someday it could revolutionize therapeutic approaches for not just the patient, but at-risk family members as well.
References mentioned in this segment:
- Diabetes Center, University of California, San Francisco
- Centers for Disease Control and Prevention's 2013 Tips From Former Smokers campaign, including 1-800-QUIT NOW, a number that links callers to their state quitlines. The website is www.cdc.gov/tips and features information on the campaign, as well as information on how to quit smoking from the National Cancer Institute's www.smokefree.gov
Host: The Endocrine Society
Diabetes Highlights from ENDO, the 95th Annual Meeting of The Endocrine Society. The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology. In this program, you will hear from global thought leaders on the important role of diabetes in your practice, new technologies, emerging therapies and research.
Diabetes Diagnosis and Management is presented by The Endocrine Society and its Hormone Health Network. This annual workshop focuses on current issues in clinical diabetes management and provides state-of-the art updates. The complete Diabetes Diagnosis and Management recording is free on endosessions.org. To hear more from ENDO 2013, visit endosessions.org
Program Highlights Listen to hear these global thought leaders:
- Carol Wysham, MD, University of Washington School of Medicine, Spokane, WA provides an overview of the key presentations from this year's meeting
- Robert Eckel, MD, University of Colorado, Aurora, CO shares his research on the emerging cardiovascular disease risk factors
- Edmond Ryan, MD, University of Alberta, Edmonton, Alberta, Canada discusses the screening and diagnosing of gestational diabetes
- Steven Kahn, MB, ChB, VA Puget Sound Health Care System, Seattle, WA, reviews the relationship of the …
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining Dr. Alan Brown is Revathi Balakrishnan, MD, MPH, a general cardiology fellow at NYU and winner of the NLA Young Investigator Competition. Dr. Balakrishnan's research, titled "Prevalence of unrecognized prediabetes, diabetes and metabolic syndrome in patients undergoing non-urgent PCI," found that nearly 1 out of every 10 patients admitted to the NYU cardiac catheterization lab had diabetic hemoglobin A1c levels (6.5 and over) without a prior diagnosis of diabetes. An even larger proportion had prediabetes (57%) and metabolic syndrome (54%). Put another way, only 30% of the patients undergoing PCI had a normal glycemic status on admission. Drs. Balakrishnan and Brown reflect on these concerning results and discuss the need for a call to action among preventive cardiologists.
Guest: Paresh Dandona, MD, PhD
Host: Farhad Zangeneh, MD
Host Dr. Farhad Zangeneh welcomes Paresh Dandona MD, PhD, Professor and Chief of Endocrinology in the Department of Medicine at the University of Buffalo. His Specialty and Research Focus are in Endocrinology, Diabetes and Metabolism. He is also the Founder & Medical Director of the Diabetes-Endocrinology Center of Western New York. In this program, Dr. Dandona will be discussing insulin induced cardioprotection, inflammatory and oxidative stress in acute myocardial infarction. He will also review hyperglycemia and cardiotoxicity in acute myocardial infarction. Please take a listen!
Guest: Robert A. Rizza, MD
Host: Farhad Zangeneh, MD
What are the sources of glucose in the body? Is diabetes a pancreatic disease or a hepatic disease? What is the importance of glucose toxicity in Type 1 or Type 2 diabetes patients? To answer these questions and many more, join our host Dr. Farhad Zangenh in a discussion with Dr. Robert Rizza, an authority in the regulation of carbohydrate metabolism in humans, and the Executive Dean for Research at Mayo Clinic. Download the podcast and listen in!
Host: Farhad Zangeneh, MD
Guest: James R. Gavin, III, MD, PhD
Host Dr Farhad Zangeneh welcomes James R. Gavin III, MD, PhD, clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. Together they will explore the trends in the growth of diabetes in African Americans, the policies needed to address these problems, and some of the barriers that prevent better outcomes in diabetes care for African Americans and other high-risk minorities.
James R. Gavin III, MD AND PHD, clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. Dr. Gavin serves as CEO and Chief Medical Officer of Healing Our Village, Inc. He also belongs to a number of organizations, including the Institute of Medicine, the American Diabetes Association (ADA), the American Society of Clinical Investigation, the American Association of Physicians, and the Atlanta Rotary Club.
Guest: Kathleen "Kittie" Wyne, MD, PhD, FACE
Host: Farhad Zangeneh, MD
Host Dr. Farhad Zangeneh welcomes Dr. Kathleen "Kittie" Wyne from the The Methodist Hospital Research Institute (TMHRI) in Houston where she also coordinates their clinical research program in The Diabetes Research Center. Dr. Wyne discusses the changing classification of diabetes and pre-diabetes and how and when we should make the diagnosis. She also discusses the criteria for both diabetes and pre-diabetes and the tools available for clinicians.
Guest: George Grunberger, MD, FACP, FACE
Host: Farhad Zangeneh, MD
Host Dr. Farhad Zangeneh welcomes Dr. George Grunberger on a discussion on how to attain the best glucose control for our patients and how to do it safely. The discussion stems from altering lifestyle changes for our patients, addressing how to set individualized targets for our patients and identifying whats the best course of action.
Dr. George Grunberger, founder and chairman of the Grunberger Diabetes Institute in Bloomfield Hills, Michigan. He is Clinical Professor of Internal Medicine and Molecular Medicine & Genetics at Wayne State University School of Medicine in Detroit. Dr. Grunberger has published well over 100 original peer-reviewed manuscripts in addition to reviews and book chapters. His research spans subjects from molecular underpinning of insulin resistance to clinical studies on diabetes and its complications.
Guest: Dean A. Bramlet, MD, FACC, FACP
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Recently, the FDA released data that claimed some the adverse events of statin therapy may lead to diabetes. But, how great are those adverse events? Should physicians and their patients have great concern? Listen in as Dr. Alan Brown welcomes Dean Bramlett, MD as they discuss statin safety, statin toxicity and the overall effectiveness of statins. Dr. Bramlett is the medical director of the Heart and Lipid Institute of Florida in St. Petersburg, Florida; and, assistant consultant professor at Duke University.
Brought to you by:
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Spencer Kroll, MD, PhD
The Food and Drug Administration has warned that patients taking cholesterol-fighting statins face a small increase in the risk of higher blood-sugar levels and of being diagnosed with diabetes. There has been conflicting information from several large trials about the effects of statin therapy on the development of diabetes and glycemic control.
Join host Dr. Alan Brown and Dr. Spencer Kroll, diplomate of the American Board of Clinical Lipidology and a board certified Internist. He also serves on the board of directors of the Northeast Lipid Association and runs The Cholesterol Treatment Center, a lipid clinic in Marlboro, New Jersey.
Host: Matt Birnholz, MD
This program will address the increasing prevalence of overweight, obese and type 2 diabetes conditions in our patient population. Physicians and healthcare professionals are confronted with multiple treatment and management challenges for type 2 diabetes. Treatment goals and care-delivery systems often present barriers to patients and clinician in achieving recommended therapeutic targets. These barriers will be identified along with suggested resources to assist in addressing these obstacles.
Presenting this Prova Education Activity is Dr. Brian McDonough, Clinical Professor of Family Medicine at Temple University School of Medicine and Chairman of the Department of Family Medicine at St. Francis Hospital.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other Prova Education Activities, visit http://www.provaeducation.com
Host: Matt Birnholz, MD
ReachMD, in cooperation with HealthDay, Presents Conference Coverage of the 71st Annual Meeting of the American Diabetes Association, held from June 24 to 28 in San Diego.
This year's meeting attracted more than 14,000 participants from around the world, including scientists, physicians, and other health care professionals. The conference highlighted the latest advances in diabetes research and improving patient care, with presentations focusing on treatment recommendations and advances toward a cure for diabetes.
Guest: Janis Roszler, CDE, RD, LD/N
Host: Steven Edelman, MD
About half of men with diabetes experience some kind of sexual dysfunction, and the numbers for women are not far behind. This week's guest, Janis Roszler, ceritified diabetes educator and marriage and family therapist, discusses the connection between sexual function and both physical and emotional well-being in patients living with diabetes. She makes the case for adding sexual function to the list of issues we talk about with patients who have diabetes. What are the causes of sexual dysfunction in these patients? Could drugs that help men also help women? Dr. Steven Edleman hosts.
Guest: Eric Rackow, MD
Host: Steven Edelman, MD
The percentage of healthcare spending on chronic illnesses is increasing exponentially; critically for patients with diabetes. How can healthcare providers help their aging population to manage their diabetes and avoid costly hospital stays through home care management? Join host Dr. Steven Edelman and his guest, professor of medicine at the New York University School of Medicine, Dr. Eric Rackow, as they discuss new approaches for home care management strategies for patients living diabetes.
Guest: Simon Heller, MD
Host: Steven Edelman, MD
In 2004 the American Diabetes Association working group defined the threshold of hypoglycemia as 70 mg/dl. The clinical definition continues to attract controversy with a standard vs. dynamic solution. What are considerations that need to be made in terms of the clinical definition of hypoglycemia? Join host Dr. Steven Edelman and his guest, professor of clinical diabetes at the University of Sheffield, Dr. Simon Heller, as they discuss the challenge with the current threshold of hypoglycemia.
Guest: Patrick O'Connor, MD
Host: Steven Edelman, MD
A push away from the "one size fits all" approach to diabetes care, including subgroup analyses, patient preference, genetic factors and electronic records, is changing the way healthcare providers are caring for their patients. How do healthcare providers reflect these changes in their practices? Join host Dr. Steven Edelman and his guest, clinician of family medicine and senior investigator for HealthPartners, Dr. Patrick O'Connor, as they discuss a personalized approach to diabetes management.
Guest: Juan Pablo Frías, MD
Host: Steven Edelman, MD
Patients living with type 1 diabetes who are involved in athletics present particular challenges to approaching to their management, medication regimen and nutrition. How can healthcare professionals help their type 1 athletes optimize their performance and manage their diabetes? Join host Dr. Steven Edelman and his guest, director of research at TeamType1, Dr. Juan Frias, as they discuss restrictions, research, monitoring and adjusting insulin therapy for endurance type 1 athletes.
Guest: William Polonsky, PhD, CDE
Host: Timothy Bailey, MD
A majority of type 2 patients do not understand the benefits of structured self-monitoring of blood glucose and healthcare professionals lack the time to explain the values and the time to review the values themselves. What is the benefit of structured self-monitoring of blood glucose in patients with type 2 diabetes? Join guest host Dr. Timothy Bailey and his guest, founder of the Behavioral Diabetes Institute, Dr. William Polonsky, as they discuss the challenges and barriers for both healthcare professionals and patients with structured self-monitoring of blood glucose.
Guest: Candis Morello, PharmD, CDE
Host: Steven Edelman, MD
Medication adherence is one of the most challenging aspects of managing patients with diabetes. The majority of diabetes patients taking more than one oral agent do not adhere to their prescribed regimens. What is the key to successful adherence to drug regimens in patients living with diabetes? Join host Dr. Steven Edelman and his guest, associate professor of clinical pharmacy at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, Dr. Candis Morello, as they discuss results from a recent study on medication adherence for patients living with diabetes.
Host: Steven Edelman, MD
Guest: Azza El-Remessy, PhD, RPh
Retinopathy is one of the most common complications for patients living with diabetes but there are few treatment options and no early-stage interventions. How is research helping to pinpoint potential targets for early intervention and a possible oral treatment? Join host Dr. Steven Edelman and his guest, assistant professor and director of clinical and experimental therapeutics at the University of Georgia, Dr. Azza El-Remessy, as they discuss the latest research into the potential of statins to prevent diabetic-related blindness.
Guest: George Blackburn, MD, PhD
Host: Maurice Pickard, MD
Food nutrition labels are becoming ubiquitous— in restaurants, on the front of packaged food, and soon, on meat products. But is all of this nutrition information actually impacting consumer behavior and encouraging healthier food choices? Hosted by Dr. Maurice Pickard's guest is Dr. George Blackburn, associate professor of surgery and nutrition, associate director of the division of nutrition, and the S. Daniel Abraham chair in nutrition medicine at Harvard Medical School, says nutrition labeling is beneficial, but all of the information can be overwhelming. How can we help consumers and patients, find clarity in the food aisles, and steer away from marketing "nutrition keys" featured on the front of many packaged foods? How could nutrition fact labels be re-designed to improve consumer understanding?
Guest: Tom Baranowski, PhD
Host: Steven Edelman, MD
How are video games showing promise as a behavior change strategy to improve children's diets? Newly-funded video-game programs are specifically designed to lower risk of type 2 diabetes and obesity in children. Join host Dr. Steven Edelman and his guest, professor of pediatrics at Baylor College, Dr. Tom Baranowski as they discuss innovative approaches to behavior change incorporating video games for children. Watch trailers for these games at www.archimage.com.
Guest: Matthew Riddle, MD
Host: Steven Edelman, MD
Patients on insulin therapy require personalized approaches to their mealtime intervention. What are the choices for patients who need something more to control glucose after meals? Join host Dr. Steven Edelman and his guest, professor of medicine at the Oregon Health & Science University, Dr. Matthew Riddle as they discuss meal time interventions for the treatment of type 2 diabetes.
Guest: Diana Zuckerman, PhD
Host: Maurice Pickard, MD
The lap-band device dramatically reduces the size of a patient's stomach, and as such, it can be effective for weight loss in very obese patients. It offers at least one major advantage over gastric bypass surgery, in that the lap-band can be removed. But can the lap-band procedure also be safe and effective for patients who are even slightly obese, or do the potential risks outweigh the benefits for these patients? Dr. Diana Zuckerman, president of the National Research Center for Women & Families and its cancer prevention and treatment fund in Washington, D.C., discusses the criteria for patients to receive lap-banding. What concerns surround the issue of lowering the body-mass index (or BMI) threshold for patients eligible for this procedure? What are the long-term risks of lap-bands? Dr. Maurice Pickard hosts.
Guest: R. Keith Campbell, BPharm, MBA
Host: Steven Edelman, MD
Changes in both care and treatment of diabetes reflect trends in healthcare that may need revision. How can healthcare professionals benefit from new pharmacotherapies for their patients living with diabetes? Join host Dr. Steven Edelman and his guest, professor of pharmacy, Keith Campbell, as they discuss trends in healthcare that may require revisions for the care of people living with diabetes.
Guest: Lois Jovanovic, MD, MACE
Host: Steven Edelman, MD
Universal guidelines in screening, diagnosis and early treatment for diabetes and pregnancy are presenting opportunities for the physician and patient to better manage their diabetes and the health of the newborn babies. What are the standards and what is the clinical relevance? Join host Dr. Steven Edelman and his guest, chief scientific officer of the Sansum Diabetes Research Institute, Dr. Lois Jovanovic, as they discuss the need to screen all pregnant women for diabetes.
Host: Janice Baker, MBA, RD, CDE, CNSC
Guest: Monika Woolsey
There are many challenges in overall diabetes management relative to a patients' mindful integration of food and behavior. What do healthcare professionals need to know to help their patients with diabetes better manage diet, stress and physical activity? Join guest host Janice Baker, CDE, RD and her guest, president and founder of "After The Diet" network, Monika Woolsey, RD, as they discuss the biochemistry and appetite regulation of diabetes and diet.
Guest: William Polonsky, PhD, CDE
Host: Janice Baker, MBA, RD, CDE, CNSC
Stress is an integral element in the management of diabetes. What are key questions healthcare professionals can ask of their patients dealing with diabetes-related stress? Join guest host Janice Baker, CDE, RD and her guest, founder of the Behavioral Diabetes Institute, Dr. William Polonsky, as they discuss the basics of stress and diabetes and we can better help our patients living with diabetes.
Guest: John Buse, MD, PhD
Host: Steven Edelman, MD
The recent American Diabetes Association / European Association for the Study of Diabetes consensus panel produced their treatment algorithm to control glycaemia in type 2 diabetes. How can healthcare professionals treating patients with type 2 diabetes provide additional prandial intervention to reach A1c targets? Join host Dr. Steven Edelman and his guest, professor of medicine at the University of North Carolina School of Medicine, Dr. John Buse, as they discuss the results of the glargine-exenatide combination study and its implications for a preferred treatment algorithm.
Guest: Vivian Fonseca, MD, FRCP
Host: Steven Edelman, MD
When should healthcare professionals treating patients with type 2 diabetes consider using insulin or incretin treatment or both? Join host Dr. Steven Edelman and his guest, president-elect of the American Diabetes Association and professor of medicine at Tulane University, Dr. Vivian Fonseca, as they discuss comparative and contrasting effects of both insulin and incretin treatment, the incretin effect and the clinical efficacy and safety of incretin-based therapies.
Guest: Alberto Hayek, MD
Host: Steven Edelman, MD
Diabetes research is the cornerstone for new opportunities in the treatment of patients living with diabetes. How will the newly formed Pediatric Diabetes Research Center serve this goal? Join guest host, certified diabetes educator Janice Baker and Dr. Alberto Hayek, professor of pediatrics and co-director of the UC San Diego's Pediatric Diabetes Research Center, as they discuss the need for collaboration in both biochemistry, molecular and cell-based therapies for the treatment of diabetes.
Guest: Christine Kessler
Host: Mimi Secor, DNP, FNP-BC, FAANP
What makes Americans fat? Diet isn't entirely to blame. Christine Kessler, who is a nurse practitioner in the department of endocrinology and metabolic medicine at a Washington, DC, teaching hospital, joins host Mimi Secor to discuss the many variables that are attributed to obesity in this country. They also look at what nurse practitioners can do to help their patients come up with strategies for living healthier lives.
Guest: G. Alexander Fleming, MD
Host: Bruce Bloom, DDS, JD
Researchers are looking at hundreds of ways to treat and cure type one diabetes. Most of the advances so far have come in newly diagnosed children. Is there anything on the horizon to help adults with established type one diabetes? Dr. Alexander (Zan) Fleming, chairman and chief medical officer of Exsulin, joins host Dr. Bruce Bloom to discuss the new therapies for reversing established diabetes.
Guest: Carmella Evans-Molina, MD, PhD
Host: Bruce Bloom, DDS, JD
As the epidemic of type 2 diabetes in the United States grows, researchers are investigating hundreds of ways to treat and cure diabetes. Some of these methods include exogenous insulin, while other ideas being explored require more complex changes in our understanding of cellular biology. Dr. Carmella Evans-Molina, assistant professor at the Indiana University School of Medicine, who holds a faculty appointment in the division of endocrinology, diabetes, and metabolism and the Herman B Wells Center for Pediatric Diabetes Research, joins us to discuss molecular mechanisms of diabetes, and potential methods of prevention related to these mechanisms. Dr. Bruce Bloom hosts.
Guest: Steven Wittlin, MD
Host: Lee Freedman, MD
It is often thought that patients with diabetes have more "silent" heart disease than patients without diabetes: Coronary artery disease is a leading cause of death among these patients. But is screening all asymptomatic patients with diabetes for the condition prudent, or should we exercise caution when considering cardiac screening? Dr. Steven Wittlin, associate professor of medicine and clinical director of the endocrine/metabolism division at the University of Rochester in New York, makes screening recommendations based on the recent Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Dr. Lee Freedman hosts.
Guest: Carolyn Paris, MD
Host: Mary Leuchars, MD
Improved living conditions and hygiene may be contributing to the rise of type 1 diabetes in children, but does the "hygiene hypothesis" fully explain the onset of type 1 diabetes in this population? What factors might explain the increased incidence of type 1 diabetes among pediatric patients in the US, Sweden and Finland, in particular? Dr. Carolyn Paris, pediatrician and emergency medicine specialist at the Center for Clinical and Translational Research at Seattle Children's Hospital, explores the indirect evidence that examines environmental influences in the development of type 1 diabetes in children. Dr. Mary Leuchars hosts.
Guest: Tatjana Rundek, MD, PhD
Host: Maurice Pickard, MD
Hundreds of millions of people may have insulin resistance worldwide. What is the connection between insulin resistance and the risk of ischemic stroke? Dr. Tatjana Rundek, associate professor of neurology and director of the clinical translational research division in the department of neurology of the Miller School of Medicine at the University of Miami, Florida, discusses her research on the risk of developing ischemic stroke among non-diabetic patients with insulin resistance with host Dr. Maurice Pickard. How can lipid-lowering medications help reduce the risk of stroke for non-diabetic patients with insulin resistance, and are any other medications on the horizon for these patients?
Guest: Hugh Tildesley, MD
Host: Lee Freedman, MD
Metformin is often the first line of therapy for patients with type 2 diabetes: it is relatively inexpensive, available, and has proven efficacy. However, metformin is contraindicated for patients with renal insufficiency, a common comorbidity in diabetes. Do the benefits of metformin outweigh the risks for those with renal insufficiency, or should we use caution when considering metformin for these patients? Dr. Hugh Tildesley, clinical professor in the department of medicine, division of endocrinology at the University of British Columbia at St. Paul's Hospital in Vancouver, Canada, considers the safety of metformin in patients with diabetes. What approach should clinicians use when considering metformin for patients with type 2 diabetes who have some degree of renal impairment? Dr. Lee Freedman hosts.
Guest: Craig Wargon, DPM
Host: Steven Edelman, MD
Patients with diabetes commonly need treatment for peripheral neuropathy. What are common symptoms and what should a physician be looking for in each patient visit? Join host Dr. Steven Edelman and his guest, practicing physician in the division of podiatric surgery at Kaiser Permanente, Dr. Craig Wargon, as they discuss symptoms, treatment and the need to glycaemic control in patients with diabetes.
Guest: James Laidler, MD
Host: Bruce Japsen
The move to re-cast high fructose corn syrup as "corn sugar" come out of the demonization of high fructose corn syrup by some in the medical community. But is high fructose corn syrup's reputation scientifically justified, and what does it mean for physicians and their patients? Dr. Jim Laidler, an MD and researcher in the area of molecular biology, talks with host Bruce Japsen about the much-maligned high fructose corn syrup and whether it is worse for health than other sugars and common substitutes.
Guest: Patti Duprey
Host: Mimi Secor, DNP, FNP-BC, FAANP
Chronic disease is on the rise in the United States — especially diabetes. More than 57 million Americans suffer from pre-diabetic symptoms. With a shortage or primary care doctors, who will take on the role of treating these patients? Nurse Practitioner Patty Duprey, director of the Diabetes Center in North Conway, New Hampshire, joins host Mimi Secor to discuss why NPs are in the perfect position to take over care of patients with diabetes and why a team approach and teaching patients self-management skills are the keys to successful treatment.
Guest: Emmanuel Baetge, PhD
Host: Steven Edelman, MD
Current stem cell therapy research is leading the way into producing functional pancreatic, insulin-producing cells. How will this translate into clinical trials and human therapy for diabetes from a scale, delivery and efficacy position? Join host Dr. Steven Edelman and his guest Dr. Emmanuel Baetge, chief scientific officer of Viacyte, Inc., as they discuss the benefits of stem cell research therapy for diabetes.
Guest: Jennifer B. Green, MD
Host: Steven Edelman, MD
What is known about the relationship between glucose control and cardiovascular disease in diabetes? The recent Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial provides some interesting results on the relationship between type 2 diabetes and silent myocardial infarction. Join host Dr. Steven Edelman and his guest, assistant professor of medicine in the division of endocrinology, metabolism and nutrition at Duke University, Dr. Jennifer Green, as they discuss the role of glycemic control to cardiovascular disease in both sexes.
Guest: David Kendall, MD
Host: Steven Edelman, MD
The assessment of intensive glycemic control in preventing cardiovascular disease is unclear. Discrepancies in recent clinical trials such as ACCORD, ADVANCE, PROactive and UKPDS 80 may reflect difference in study design and patients, versus glycemic control. How can using the Archimedes model illuminate this quandary? Join host Dr. Steven Edelman and his guest, chief scientific and medical officer of the American Diabetes Association, Dr. David Kendall, as they discuss the effect of glycemic control on macrovascular outcomes in patients with diabetes.
Guest: Stanley Schwartz, MD
Host: Steven Edelman, MD
Guidelines that avoid the use of oral antidiabetes agents associated with hypoglycemia and weight gain are becoming increasingly popular in treating patients with diabetes. What are we learning about incretin-based therapies in both the intensive care and emergency medicine departments and perioperatively? Join host Dr. Steven Edelman and his guest, associate professor of medicine at the University of Pennsylvania, Dr. Stanley Schwartz, as they discuss the surprising results in both intensive care, emergency medicine and perioperative periods using incretin-based therapies.
Guest: Ralph A. DeFronzo, MD
Host: Steven Edelman, MD
New information on the state of impaired glucose tolerance indicates that the level of beta cell loss is greater than once considered. New treatment regimens are being considered to combat both the insulin sensitivity and beta cell loss for type 2 diabetes. What do health care professionals need to understand about the critical first steps in both the assessment and treatment of patients with type 2 diabetes? Join host Dr. Steven Edelman and his guest, professor of medicine at the University of Texas Health Science Center, Dr. Ralph DeFronzo, as they discuss the potential of early combination and triple therapy to preserve beta cell function.
Guest: Fred Toffel, MD
Host: Steven Edelman, MD
Are the current ADA guidelines for inpatient care enough in the management of patients with diabetes? How are areas such as identification, assessment, glycemic control and nutrition therapy integrated? How are we approaching optimal glycemic control for inpatient care? Join host Dr. Steven Edelman and his guest, endocrinologist in Las Vegas, Nevada, Dr. Fred Toffel, as they discuss unique approaches to inpatient care for patients with diabetes.
Guest: Philip Zeitler, MD, PhD
Host: Steven Edelman, MD
The emergence of type 2 diabetes in both children and adolescents suggests a relationship between insulin sensitivity and puberty. What are we learning from recent studies and clinical research? Join host Dr. Steven Edelman and his guest, professor of pediatrics at the University of Colorado, Dr. Philip Zeitler as they discuss recent studies and clinical data that may shed light on this relationship.
Guest: Susan Scanland, MSN, CRNP, GNP-BC
Host: Mimi Secor, DNP, FNP-BC, FAANP
How can we limit the risk of Alzheimer's disease? New research suggests a correlation between obesity, type 2 diabetes and dementia. Susan Scanland, gerontological nurse practitioner, discusses this research with host Mimi Secor. She discusses how Alzheimer's, weight and waist size seem to be related, and how clinicians can help patients reduce their risk of Alzheimer's disease.
Host: Mark Chyna, MD
Hear highlights from research on the management of obesity, endocrine disorders, diabetes, menopause, and thyroid cancer presented at the Endocrine Society's 92nd Annual Meeting and Expo. The meeting took place June 19 to 22, 2010, in San Diego.
Host: Mark Chyna, MD
This round-up describes highlights from the American Diabetes Association's 70th Scientific Sessions, June 25th through the 29th in Orlando, Florida, covering cutting-edge research, treatment recommendations, and advances toward a cure for diabetes.
Guest: Candis Morello, PharmD, CDE
Host: Steven Edelman, MD
The management of diabetes is a sophisticated multi-disciplinary approach. There are multiple benefits to both the physician treating diabetes patients and the patients themselves by increasing the role of the pharmacist to provide a collaborative approach to care and placing the patient at the center. Join host Dr. Steven Edelman and his guest, pharmacist from the Skaggs School of Pharmacy Sciences at the University of California, San Diego, Dr. Candis Morello, as they discuss the benefit of the increasing role of the pharmacist in the management of diabetes.
Guest: Jim Flood
Host: Janice Baker, MBA, RD, CDE, CNSC
It is well established that exercise is a critical component in the management of diabetes, but many diabetes patients struggle with exercise. Physical therapists are the "exercise experts" in the guidance of patients' overall care. What are the benefits of physical therapy for patients living with diabetes? Join guest host, Janice Baker, RD, CDE, and her guest, physical therapist in San Diego, California, Jim Flood, as they discuss the benefits of designing an exercise plan for their patients.
Guest: Angela Norton, RN, CDE, PHN
Host: Steven Edelman, MD
Diabetes educators focus on helping patients living with diabetes and related conditions achieve behavior change goals and lead to better clinical outcomes and improved health status. How has the role of the certified diabetes educator changed in the management of diabetes? Join host Dr. Steven Edelman and his guest, diabetes educator at SHARP Healthcare, Angela Norton, as they discuss the benefits and increasing role of the diabetes educator in the management of diabetes.
Guest: Janice Baker, MBA, RD, CDE, CNSC
Host: Steven Edelman, MD
The prevalence of type 2 diabetes increases with age, with an estimated 8.6 million Americans over the age of 60 diagnosed with diabetes, and a growing number at-risk for developing diabetes with age. Our elderly face unique diabetes management challenges. Join host Dr. Steven Edelman and his guest, registered dietitian and Certified Diabetes Educator Janice Baker, as they discuss the unique challenges in caring for our elderly patients with diabetes.
Guest: Isaac Schiff, MD
Host: Bruce Bloom, DDS, JD
In the 80-year history of hormone therapy, it has been alternately embraced and rejected. Case in point: the original term, hormone replacement therapy, came to be seen as highlighting a negative state, and was changed to simply hormone therapy. Why has the pendulum swung so frequently back and forth? What is the latest "timing hypothesis," and will it again change our evaluation of hormone therapy? Host Dr. Bruce Bloom explores the studies and new thinking, the benefit for bone density, the risk of breast cancer, and more, with Dr. Isaac Schiff, chief of the Vincent Obstetrics and Gynecology Service at Massachusetts General Hospital and the Joe Vincent Meigs Professor of Gynecology at Harvard Medical School.
Series Produced in Cooperation With
Guest: Janet Trowbridge
Host: Steven Edelman, MD
There are a number of skin conditions that affect people with diabetes: xerosis, acanthosis nigrican, necrobiosis lipoidica diabeticorum and more. What do healthcare providers need to know to diagnose and treat their patients? Join host Dr. Steven Edelman and his guest, dermatologist specializing in diabetes, Dr. Janet Trowbridge, as they discuss skin conditions in patients with diabetes.
Guest: Scott Levin, MD
Host: Lee Freedman, MD
Trauma patients with injury to one or more limb often have additional systemic injuries that need to be considered during treatment. One approach to limb salvage is the ortho-plastic technique, which involves integrated soft tissue and bone. This conversation covers some of the latest advances in limb salvage techniques that might benefit trauma patients, as well as those with diabetes or peripheral vascular disease. Dr. Scott Levin, professor and chair of orthopaedic surgery and professor of plastic surgery at Penn Medicine, discusses strategies for avoiding amputation. Dr. Lee Freedman hosts.
Produced in Cooperation with
Guest: Wilfred Fujimoto, MD
Host: Steven Edelman, MD
The estimated prevalence and incidence of diabetes for Asian and Pacific-Islander youth is growing at an incremental rate. These populations present unique challenges in both diagnosis and treatment. Join host Dr. Steven Edelman and his guest, professor emeritus of internal medicine at the University of Washington, Dr. Wilfred Fujimoto as they discuss clinical characteristics, diagnosis, and unique challenges in the treatment of diabetes in this population.
Guest: Rachel Kim, MD
Host: Steven Edelman, MD
Diabetes may affect the musculoskeletal system in a variety of ways. The metabolic perturbations in diabetes result in changes in the connective tissue. What are current recommendations for healthcare providers as an overall strategy in the treatment of patients living with diabetes? Join host Dr. Steven Edelman and his guest, rheumatologist at the Scripps Clinic, Dr. Rachel Kim, as they discuss musculoskeletal complications, intervention and treatment.
Guest: Matthias von Herrath, MD
Host: Steven Edelman, MD
Development of a combination therapy is showing significant promise in type 1 diabetes when caught in the early stages. What are some immuno-therapies currently being evaluated for treating type 1 diabetes? Join host Dr. Steven Edelman and his guest, director of the Center for Type 1 Diabetes Research at the La Jolla Institute for Allergy and Immunology, Dr. Matthias von Herrath, as they discuss histopathology, antigen-specific therapy, anti-CD3d antibodies and more.
Host: Steven Edelman, MD
Guest: Joe Piscatella
According to the National Institutes of Health, 85% of physicians state they are not effective in helping patients make healthy dietary changes. What are the obstacles for our healthcare professionals treating patients with diabetes? Join host Dr. Steven Edelman and his guest, best-selling author and national speaker, Joe Piscatella, as they discuss strategies and techniques for healthcare professionals in helping their patients institute and maintain a healthy diet.
Guest: Stephen Ponder, MD, CDE
Host: Steven Edelman, MD
The emergence of type 2 diabetes in children and adolescents over the past 20 years represents a shift in pediatric chronic disease. Join host Dr. Steven Edelman and his guest, professor of pediatrics and director of the Children’s Diabetes and Endocrine Center of South Texas at Driscoll Children’s Hospital, Dr. Stephen Ponder, as they discuss key challenges in both diagnosis and medical management of this group.
Guest: Bruce Buckingham, MD
Host: Steven Edelman, MD
The developing artificial pancreas carries tremendous potential for the treatment of diabetes. What is research telling us about the various steps to the implementation of the system? Join host Dr. Steven Edelman and his guest, pediatric endocrinologist and professor of medicine at Stanford University, Dr. Bruce Buckingham, as they discuss design, function, implementation, and obstacles to developing the artificial pancreas.
Guest: Richard Bergenstal, MD
Host: Steven Edelman, MD
The ACCORD, ADVANCE and VA Diabetes Trials seem to indicate that there is no real benefit of intensive glycemic control on cardiovascular events in patients with type 2 diabetes. Join host Dr. Steven Edelman and his guest, executive director of the International Diabetes Center at Park Nicollet, Dr. Richard Bergenstal, as they discuss the implications on clinical care and benefits of glycemic control.
Guest: Anne-Marie Felton
Host: Steven Edelman, MD
World Diabetes Day marks the annual global awareness campaign for diabetes by the International Diabetes Federation. The campaign’s theme of "diabetes education and prevention" is scheduled for five years. How will the IDF implement this broad campaign for both the health care professionals and people living with diabetes? Join host Dr. Steven Edelman and his guest, vice president of the International Diabetes Federation, Anne-Marie Felton, as they discuss World Diabetes Day and the need for diabetes education and prevention.
Guest: Lisa Kroon, PharmD, CD
Host: Steven Edelman, MD
The new class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which stimulate the pancreas to make more insulin after eating a meal, may be changing the way we treat people with type 2 diabetes. Join guest host, Dr. Candis Morello and her guest, professor of clinical pharmacy in the School of Pharmacy at the University of California San Francisco, Dr. Lisa Kroon, as they discuss the use of DPP-4 therapy in the treatment of type 2 diabetes.
Host: Candis Morello, PharmD, CDE
Guest: Brookie Best, PharmD
New drug delivery technologies are changing one of the key therapeutic challenges of insulin delivery in the management of diabetes. Join guest host Dr. Candis Morello and her guest, Dr. Brookie Best, assistant clinical professor of pharmacy and pediatrics at University of California San Diego, as they discuss the emerging new technologies being developed in this space.
Guest: Irl Hirsch, MD, MACP
Host: Steven Edelman, MD
Lowering blood sugar levels in critically ill patients is a widely embraced practice. But according to the results of the NICE-SUGAR study, lowering blood glucose levels in ICU patients may not be safe. Join host Dr. Steven Edelman and his guest, Dr. Irl Hirsch, professor of medicine and the Diabetes Treatment and Teaching chair at the University of Washington in Seattle, as they discuss the results of the NICE-SUGAR study and its implications for treating critically ill patients.
Host: Steven Edelman, MD
Guest: Lorena Drago, MS, RD, CDN, CDE
According to a recent study, people with type 2 diabetes are not meeting important nutritional recommendations. Finding the correct balance of carbohydrates, protein and fat along with portion control and moderation is a challenge. Our guest, dietitian and certified diabetes educator, Lorena Drago, discusses the variance in recommended diets for people living with diabetes. Join host Dr. Steven Edelman to learn more.
Guest: John Buse, MD, PhD
Host: Steven Edelman, MD
Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Guest: Kelly Close, MBA
Host: Steven Edelman, MD
The prevalence of diabetes complications and its associated costs represent an infrastructure that may be virtually unsustainable in the near future. Join host Dr. Steven Edelman and his guest, editor-in-chief of the diabetes publications Closer Look and Diabetes Close Up, Kelly Close, as they discuss the challenges of both regulation and reimbursement.
Guest: Susan Phillips, MD
Host: Steven Edelman, MD
The incidence of diabetes is increasing per year in the US and globally. The trend data suggests that obesity may be driving autoimmune beta cell failure. Some have questioned whether excess obesity or adiposity might be playing a role in this increased incidence of type 1 diabetes or whether healthcare professionals are not recognizing type 2 diabetes in youth. Join host Dr. Steven Edelman and his guest, pediatric endocrinologist and clinical researcher, Dr. Susan Phillips, as they discuss the challenges facing healthcare professionals in the diagnosis and treatment of diabetes in childhood.
Join us for research highlights from the American Diabetes Association's 69th Scientific Sessions. This meeting took place June 5th through 9th, in New Orleans.
Guest: David Metz, MD
Host: Lee Freedman, MD
Although gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, are relatively common, they are often indolent. However, GEP-NETs can metastasize in a small portion of the population, so physicians should be aware of symptoms and screening tools. The two most common types of GEP-NETs are categorized as carcinoids and pancreatic endocrine tumors. What distinguishes the two? Host Dr. Lee Freedman welcomes Dr. David Metz, professor of medicine and associate chief for clinical affairs in the division of gastroenterology at Penn Medicine, to discuss characteristics and diagnosis of GEP-NETs.
Produced in Cooperation with
Guest: Shazia Jamil, MD
Host: Steven Edelman, MD
Type 2 diabetes and obstructive sleep apnea have been shown to have a close relationship. Join host Dr. Steven Edelman and his guest, sleep specialist and pulmonologist Dr. Shazia Jamil, as they discuss the diagnosis and treatments of obstructive sleep apnea including continuous positive airway pressure (or CPAP) and surgery.
Guest: Kenneth Burman, MD
Host: Jennifer Shu, MD, FAAP
Thyroid disorders during pregnancy can lead to problems for the mother — miscarriage, preeclampsia and preterm delivery, among others — as well as problems for the infant, including growth delays and mental retardation. Yet women frequently go undiagnosed, because thyroid dysfunction is often subclinical or is masked by the effects of pregnancy. With more than six million pregnancies in the United States each year, would the health benefits of routine prenatal thyroid screening and treatment justify the expense? Dr. Kenneth D. Burman, director of the endocrine section at Washington Hospital Center in Washington, DC, and a professor of medicine at Georgetown University's School of Medicine, joins host Dr. Jennifer Shu to evaluate key questions in this ongoing debate.
Guest: Ian Blumer, MD
Host: Steven Edelman, MD
Type 2 diabetes is a progressive disease and most patients will eventually need insulin to achieve euglycemia. Early and aggressive management to lower blood glucose reduces the risk of complications of the disease. It can be challenging for health care professionals to decide which treatment regimen is appropriate to manage a particular patient. Join host Dr. Steven Edelman and his guest, endocrinologist and medical advisor to the Charles H. Best Diabetes Centre in Ontario, Canada, Dr. Ian Blumer, as they discuss insulin initiation strategies.
Tune in for highlights from the American Association of Clinical Endocrinologists' 18th Annual Meeting and Clinical Congress, which took place May 13th through the 17th in Houston.
Guest: Kimber Stanhope, PhD, MS
Host: Larry Kaskel, MD
Which is worse: fructose-sweetened drinks or glucose-sweetened drinks? For some time, we have lacked consensus on the degree of punishment our bodies take from drinks sugared by these common saccharines. For now, fructose may again be wearing the crown, scoring unhealthy points in abdominal adiposity, and triglyceride and LDL levels, among other categories. Nutritional biologist Dr. Kimber Stanhope, from the University of California, Davis, joins host Dr. Larry Kaskel to shed some new light on this enduring debate. The lead author of a recent study published in the Journal of Clinical Investigation on the consumption of fructose-sweetened and glucose-sweetened beverages, Dr. Stanhope also explains that there is little value in directly applying these results to fruits, because fruits confer other important health benefits.
Guest: Abraham Morgentaler, MD
Host: Maurice Pickard, MD
Testosterone therapy for men is controversial, but some new research suggests physicians might want to re-evaluate increasing the levels of testosterone in men with lower levels. Sexual dysfunction is one of the more apparent symptoms of low testosterone, but what are the other non-sexual symptoms of low "T" physicians should be aware of? What are the parameters for determining appropriate testosterone levels in our male patients? Isn't there an increased risk of developing prostate cancer among men undergoing testosterone therapy? Tune in to hear Dr. Abraham Morgentaler, associate clinical professor of surgery (urology) at Harvard Medical School and author of the book Testosterone for Life, weigh in on these and other questions surrounding testosterone therapy. Hosted by Dr. Maurice Pickard.
Guest: Evelyn Hermes-DeSantis, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
Initial therapy for patients with gastroparesis often centers on dietary changes and pharmacotherapy. If first-line therapy proves ineffective, we appear to lack a broad selection of treatment options for patients with refractory gastroparesis. Some small studies have explored the idea that botulinum toxin could be valuable in this situation. What are its proposed mechanisms of action, and what is the current thinking on its efficacy? Host Dr. Charles Turck evaluates the evidence with Dr. Evelyn Hermes-DeSantis, director of the Drug Information Service at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, and a clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey.
Guest: Laurie Goodyear, PhD
Host: Larry Kaskel, MD
Dr. Laurie Goodyear, a senior investigator and head of the section on metabolism at the Joslin Diabetes Center in Boston, discusses with host Dr. Larry Kaskel how exercise impedes the development of type 2 diabetes. Tune in to hear the implications of Dr. Goodyear's research on exercise and how it works to promote the uptake of glucose into muscles. Could an exercise pill mimic the exercise-activated glucose uptake?
Guest: Kenneth Moritsugu, MD, MPH
Host: Cathleen Margolin, PhD
The diabetes pandemic must be addressed around the globe with consideration for varying cultural and economic factors. How will countries around the world respond? And how can intervention programs that have proven successful be shared effectively across nations? Join host Dr. Cathleen Margolin as she discusses community based initiatives for diabetes with Dr. Kenneth Moritsugu, former Deputy Surgeon General and current chairman of the Johnson & Johnson Diabetes Institute.
Guest: Rita K. Cydulka, MD, MS
Host: Shira Johnson, MD
Seven percent of the adult population has diabetes, and these patients often present to primary care and emergency department physicians. What do you need to know about the medications these patients may already be taking, or that they may require once they're under your care? Understanding the effects, as well as potential complications, of the most current diabetes medications and devices is crucial when treating patients who have diabetes. Dr. Rita Cydulka, professor and vice-chair of the department of emergency medicine at Case Western Reserve University, joins host Dr. Shira Johnson to highlight the new medications and devices for managing diabetes. She also describes real-life presentations of patients who may be having problems with glucose management.
Guest: Timothy Church, MD, PhD
Host: Bruce Japsen
Motivating your patients to exercise can be a challenge. But Dr. Timothy Church of the Pennington Biomedical Research Center in Baton Rouge, Louisiana, tells host Bruce Japsen that even 15 minutes a day can help, citing research that shows even minimal exercise can be a benefit to the obesity epidemic and other diabetes risk factors.
Host: Bruce Bloom, DDS, JD
Guest: Mary Elizabeth Hartnett, MD
Almost a third of all type I and type II diabetics develop macular edema. Join host Dr. Bruce Bloom and his guest, ophthalmologist, researcher and vitreo-retinal surgeon Dr. Mary Elizabeth Hartnett, professor of opthamology at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the etiology and treatment of diabetic macular edema.
Guest: Eliot Brinton, MD, FAHA, FNLA
Host: Larry Kaskel, MD
The ADVANCE Study involved 11,140 high-risk patients with type 2 diabetes. Join host Dr. Larry Kaskel when guest Dr. Eliot Brinton explains the findings from the largest-ever study of treatments for diabetes, which provided no evidence of an increased risk of death among patients receiving aggressive treatment to lower blood glucose. Dr. Brinton highlights how the findings of the ADVANCE trial contrast the findings of the ACCORD trial, and the impact these findings will have on treatment protocols.
Brought to you by:
Guest: Gerald Bernstein, MD
Host: Bruce Japsen
Diabetes has become such a worldwide epidemic that some are turning to over-the-counter products as a way to help patients with this disease that has afflicted nearly 24 million in the U.S. alone. Dr. Gerald Bernstein, the vice president of medical affairs at Generex, a biotech company based in Toronto, tells host Bruce Japsen about nutritional products and over-the-counter options for patients with diabetes.
Guest: Susan Cornell, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
How can we best optimize pharmacotherapy for patients with Type 2 diabetes? What are the main treatment barriers to keep in mind, and what are the most common comorbidities that we might be able to treat concurrently with diabetes therapy? Dr. Susan Cornell, assistant professor of pharmacy practice at Midwestern University Chicago College of Pharmacy, takes a closer look at these questions, and also shares strategies to directly collaborate with diabetic patients in managing the consequences of their disease. Dr. Charles Turck hosts.
Guest: John Baxter, MD
Host: Larry Kaskel, MD
Dr. Larry Kaskel welcomes Dr. John Baxter to Lipid Luminations. Dr. Baxter is Senior Member at The Methodist Hospital in Houston, Texas as well at the Methodist Hospital Reasearch Institute. He will be discussing Thyroid Hormone Receptor Beta and Tissue Selective Uptake Antagonists. In particular, how they relate to the treatment of Atherosclerosis, Obesity and Diabetes. Selective thyroid hormone receptor subtype-beta (TRbeta) agonists have received attention as potential treatments for hypercholesterolemia and obesity, but have received less attention as treatments for diabetes.
Brought to you by:
Guest: Yehuda Handelsman, MD
Host: Larry Kaskel, MD
Host Dr. Larry Kaskel welcomes Dr. Yehuda Handelsman, medical director of the Metabolic Institute of America and chair of the International Committee for Insulin Resistance. Dr. Handelsman examines the relationship of insulin resistance to metabolic syndrome, as well as a series of clinical conditions associated with insulin resistance. He also highlights lifestyle modifications and other treatment measures for patients with multiple risk factors.
Brought to you by:
Guest: James A. Underberg, MD
Host: Susan Dolan, RN, JD
How do the findings from the Veterans Affairs Diabetes Trail help resolve concerns raised by the ACCORD and ADVANCE studies? Hear Dr. James A. Underberg of New York University School of Medicine as he discusses findings from all three research studies.
Guest: Larry Deeb, MD
Host: Maurice Pickard, MD
Dr. Larry Deeb, past president of medicine and science of the American Diabetes Association and clinical professor of medicine at the University of Florida College of Medicine, tells host Dr. Maurice Pickard how type 1 diabetic athletes have been able to maintain performance levels of excellence. Improvement of monitoring and insulin delivery systems allows control of glucose levels that could have only been imagined 25 years ago.
Guest: Anne Louise Peters, MD
Host: Susan Dolan, RN, JD
Athletes with diabetes face particular challenges. Dr. Anne L. Peters, author of the book Conquering Diabetes: A Cutting-Edge Comprehensive Program for Prevention and Treatment, has treated diabetic Olympic and other competitive athletes. Dr. Peters discusses issues and protective measures with host Dr. Susan Dolan.
Guest: John Buse, MD, PhD
Host: Matthew J. Sorrentino, MD, FACC, FASH
What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in mortality. Dr. John Buse, president of the American Diabetes Association and vice chair of the ACCORD Trials Steering Committee, details the confounding results of ACCORD and offers a few ideas to explain the unexpected outcomes. Dr. Matthew Sorrentino hosts.
Guest: Dariush Mozaffarian, MD
Host: Matthew J. Sorrentino, MD, FACC, FASH
The Metabolic Syndrome has been associated with an increased risk for developing diabetes and cardiovascular disease. Dr. Dariush Mozaffarian from the Division of Cardiovascular Medicine at Harvard Medical School will discuss his latest research on the Metabolic Syndrome in older adults highlighting the increase mortality found with hypertension and elevated fasting glucose.
Guest: Sandra Carson, MD
Host: Lauren Streicher, MD
Host Dr. Lauren Streicher continues her discussion with Dr. Sandra Carson, professor of obstetrics and gynecology at the Warren Alpert Medical School at Brown University, on how to tackle the issue of treating obese women. They discuss diet plans, lifestyle modifications, counseling strategies, and medications to best treat obese patients.
Guest: Suzanne Clough, MD
Host: Susan Dolan, RN, JD
Dr. Suzanne Sysko Clough is the Chief Medical Officer of WellDoc Communications, a technology based healthcare company located in Baltimore, Maryland. Hear Dr. Clough as she discusses how the WellDoc cell phone-based technology helps patients manage their diabetes.
Guest: Mira Milas, MD
Host: Maurice Pickard, MD
There are many new techniques to evaluate patients with thyroid and parathyroid disease. Dr. Mira Milas, associate professor at the Institute of Surgery, Endocrinology and Metabolism Institute at Cleveland Clinic Lerner College of Medicine, speaks about the use of ultrasound in thyroid disease detection. She also updates host Dr. Maurice Pickard on the development of a new test, TSHrmRNA, to augment intermediate FNA as well as to show if there is residual disease or recurrence. They also discuss osteoporosis found in some men with parathyroid disease.
Guest: Shelley Salpeter, MD
Host: Lee Freedman, MD
Can metformin safely improve metabolic variables such as weight, lipids, fasting glucose and onset of outright diabetes? Will the improvement in these surrogate endpoints translate into fewer events? Dr. Shelley Salpeter joins host Dr. Lee Freedman to review the rationale for and data behind using metformin in high risk individuals to prevent the onset of type II diabetes mellitus.
Guest: Brian Smith, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
When attempting to control blood sugar levels in critically ill patients, how far should we go? Host Dr. Charles Turck probes this question and more with Dr. Brian Smith, director of education in clinical services of the pharmacy department of the University of Massachussetts (UMass) Memorial Medical Center and chair of the UMass Glycemic Control Task Force. Dr. Smith examines current evidence supporting tight glucose monitoring in an intensive care setting.
Guest: Andrew Flood, PhD
Host: Gary Kohn, MD
The risk association between diabetes and colorectal cancer: what is the mechanism driving the correlation? What methods are used to study the relationship? Dr. Andrew Flood, assistant professor of epidemiology, University of Minnesota, and adjunct investigator at the National Cancer Institute, Division of Cancer Epidemiology and Genetics discusses the relationship and his research with host Dr. Gary Kohn.
Guest: Jan Berger, MD
Host: Bruce Japsen
The annual cost of diabetes care in this country is rapidly approaching $200 billion, an astonishing figure that has nearly doubled since the beginning of this decade. Dr. Jan Berger, senior vice president and chief clinical officer of the Caremark Corporation, tells host Bruce Japsen that it does not have to be this way. Patients with this potentially deadly disease must work more efficiently in coordination with their physicians toward proper management of care.